{
  "documents": [
    {
      "id": "18887130-DS-10:0",
      "text": "Name:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   F\n \nService: MEDICINE Allergies: \nNo Known Allergies / Adverse Drug Reactions\n \nAttending: ___\n \n___ Complaint:\nScheduled admit for cycle 2 of ICE\n \nMajor Surgical or Invasive Procedure:\nNone",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 0,
        "tokenCount": 84,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:1",
      "text": "History of Present Illness:\nMs. ___ is a ___ year old female with a history of follicular lymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \nthen rituximab x 6 in ___, now with transformed DLBCL who \npresents with for cycle 2 of ICE therapy. Per report, she has \nsignificant  neck and upper thoracic involvement, as well as \nmesenteric  involvement. She underwent her first cycle of ICE \nwithout complications ___ and since then has been getting \nrituxan and neupogen. On arrival to the floor, patient is feeling well. Her only \ncomplaint from her previous session of chemo was mild stomach \nupset. She denies any fevers/chills, headache, vision changes, \nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 1,
        "tokenCount": 182,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:2",
      "text": "Past Medical History:\nFollicular lymphoma stage IIA with disease recurrence\n- ___ developed worsening musculoskeletal back pain, early \nsatiety, hypoalbuminemia and found to have mesenteric mass\n- ?___ ex lap with 15 cm lobulated mass involving the \nduodenum, retroperitoneum and celiac access. Biopsies showed \nFollicular lymphomas grade II/III. Reportedly negative staging \nGallium scan. CD10+ BCL2+\n- ___ completed 6 cycles CHOP, complications included \nSVC/innominate thrombus (tPA)\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\nmarrow at completion was negative for lymphomatous involvement. - ___ PET-CT with very slight amount of increased tracer\nactivity within the posterior left supraclavicular region. No\nother areas of FDG avid disease were noted \n- ___ through ___ per records she was treated with CVP\nfollowed by course of single agent Rituxan\n- ___ through ___ surveillance imaging with no evidence of\nrecurrent disease, stable mesenteric mass. - ___ abdominal pain led to CT with no change in mass size,\nincreased conspicuity of nodular borders\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\nstable mesenteric mass with low level SUV 2.2 stable since \nprior. - ___ CT torso showed persistent mesenteric and left hilar\nlymphadenopathy. Stable right middle lobe small focus of ground\nglass opacity and adjacent subpleural fat hypertrophy, \nsuggestive\nof inflammatory process. Stable right adnexal cyst. - ___ Presented to PCP ___ ___iscomfort. Exam\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\nnormal differential, PLT 452. - ___ PET CT revealed, \"Large left cervical,\nsupraclavicular, mediastinal lymphadenopathy, and \nretroperitoneal lymphadenopathy, and small mesenteric \nlymphadenopathy, all of which is markedly FDG-avid and \nconcerning for\nlymphoma.\" SUVmax 35.5. - ___iopsy revealed diffuse large B cell\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \nare pending\n- ___ C1D1 ICE PAST MEDICAL/SURGICAL HISTORY:  \nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \n(*Known slight CN VI palsy & mild proptosis of R eye)\nHypogammaglobulinemia, \nMild GERD\nOA / LBP\nSmall Intestinal Bacterial Overgrowth\nTrochanteric Bursitis\ns/p Excisional Bx L Cervical Lymph Node\ns/p L total knee replacement ___\ns/p I&D Labial Abscess\ns/p Excision Cyst R ___ Digit of Hand Social History:\n___ Family History:\nNC",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 2,
        "tokenCount": 595,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:3",
      "text": "Physical Exam:\nADMISSION PHYSICAL EXAM:\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \nsoft palate(chronic per patient), otherwise OP is clear\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \nCV: RRR, no r/g/m \nLungs: CTA b/l\nAbdomen: Soft, NT, ND, +BS\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \non b/l shins    \nNeuro: Notable for R CN VI palsy & diminished sensation in CN \nV-1, also sluggish R CN III response to direct & indirect \nillumination, otherwise CN's grossly intact, intact muscle \nstrength all extremities, intact light sensation b/l ___\nSkin: R pheresis line c/d/i DISCHARGE PHYSICAL EXAM:\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \nsoft palate(chronic per patient), otherwise OP is clear\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \nCV: RRR, no r/g/m \nLungs: CTA b/l\nAbdomen: Soft, NT, ND, +BS\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \non b/l shins    \nNeuro: Notable for R CN VI palsy & diminished sensation in CN \nV-1, also sluggish R CN III response to direct & indirect \nillumination, otherwise CN's grossly intact, intact muscle \nstrength all extremities, intact light sensation b/l ___\nSkin: R pheresis line c/d/i Pertinent Results:\nADMISSION LABS:\n---------------\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \nMCH-31.3 MCHC-34.7 RDW-14.4\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \nBASOS-0.5\n___ 10:00AM   PLT COUNT-232#\n___ 10:00AM   ___ PTT-29.3 ___\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \nPHOS-108* TOT BILI-0.2\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \nMAGNESIUM-2.1\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \nLEUK-NEG\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___ DISCHARGE LABS:\n---------------\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \nEos-0.1 Baso-0.4\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \nK-4.1 Cl-107 HCO3-26 AnGap-13\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \nTotBili-0.1\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 3,
        "tokenCount": 637,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    },
    {
      "id": "18887130-DS-10:4",
      "text": "Brief Hospital Course:\nMs. ___ is a ___ year old female with a history of follicular \nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \nthen rituximab x 6 in ___, now with transformed DLBCL who \npresents with for cycle 2 of ICE therapy # DLBCL: Here for c2 of R-ICE. c1 R-ICE started ___ and \ncompleted without complications. She will need Neupogen D5-12 to \nsupport ___. Will continue bactrim, acyclovir and allopurinol \nfor ppx. Plan for PET-CT after ___ cycle to assess disease \nresponse to therapy.",
      "metadata": {
        "patient_identifier": "18887130",
        "note_id": "18887130-DS-10",
        "chart_time": "103284",
        "section": "General",
        "position": 4,
        "tokenCount": 129,
        "note_metadata": {
          "note_id": "18887130-DS-10",
          "subject_id": 18887130,
          "hadm_id": 20858810,
          "note_type": "DS",
          "note_seq": 10,
          "charttime": 103284,
          "storetime": 103284.775,
          "text": " \r\nName:  ___                   Unit No:   ___\r\n \r\nAdmission Date:  ___              Discharge Date:   ___\r\n \r\nDate of Birth:  ___             Sex:   F\r\n \r\nService: MEDICINE\r\n \r\nAllergies: \r\nNo Known Allergies / Adverse Drug Reactions\r\n \r\nAttending: ___\r\n \r\n___ Complaint:\r\nScheduled admit for cycle 2 of ICE\r\n \r\nMajor Surgical or Invasive Procedure:\r\nNone\r\n \r\nHistory of Present Illness:\r\nMs. ___ is a ___ year old female with a history of follicular \r\n\r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy. Per report, she has \r\nsignificant  neck and upper thoracic involvement, as well as \r\nmesenteric  involvement.  She underwent her first cycle of ICE \r\nwithout complications ___ and since then has been getting \r\nrituxan and neupogen. \r\n\r\nOn arrival to the floor, patient is feeling well.  Her only \r\ncomplaint from her previous session of chemo was mild stomach \r\nupset.  She denies any fevers/chills, headache, vision changes, \r\nsore throat, SOB, CP, abd pain, N/V/D, dysuria or new rashes.\r\n\r\n \r\nPast Medical History:\r\nFollicular lymphoma stage IIA with disease recurrence\r\n- ___ developed worsening musculoskeletal back pain, early \r\nsatiety, hypoalbuminemia and found to have mesenteric mass\r\n- ?___ ex lap with 15 cm lobulated mass involving the \r\nduodenum, retroperitoneum and celiac access.  Biopsies showed \r\nFollicular lymphomas grade II/III.  Reportedly negative staging \r\nGallium scan. CD10+ BCL2+\r\n- ___ completed 6 cycles CHOP, complications included \r\nSVC/innominate thrombus (tPA)\r\n- ___ CT showed persistent 7 x 3.5 x 9 cm oblong mass, bone\r\nmarrow at completion was negative for lymphomatous involvement.\r\n- ___ PET-CT with very slight amount of increased tracer\r\nactivity within the posterior left supraclavicular region. No\r\nother areas of FDG avid disease were noted \r\n- ___ through ___ per records she was treated with CVP\r\nfollowed by course of single agent Rituxan\r\n- ___ through ___ surveillance imaging with no evidence of\r\nrecurrent disease, stable mesenteric mass.\r\n- ___ abdominal pain led to CT with no change in mass size,\r\nincreased conspicuity of nodular borders\r\n- ___ PET-CT with L. hilar LN PET-avid to SUV 7.9, otherwise\r\nstable mesenteric mass with low level SUV 2.2 stable since \r\nprior.\r\n- ___ CT torso showed persistent mesenteric and left hilar\r\nlymphadenopathy. Stable right middle lobe small focus of ground\r\nglass opacity and adjacent subpleural fat hypertrophy, \r\nsuggestive\r\nof inflammatory process. Stable right adnexal cyst.  \r\n- ___ Presented to PCP ___ ___iscomfort. \r\nExam\r\nrevealed new adenopathy. Labs notable for LDH 341, WBC 10.1,\r\nnormal differential, PLT 452. \r\n- ___ PET CT revealed, \"Large left cervical,\r\nsupraclavicular, mediastinal lymphadenopathy, and \r\nretroperitoneal lymphadenopathy, and small mesenteric \r\nlymphadenopathy, all of which is markedly FDG-avid and \r\nconcerning for\r\nlymphoma.\" SUVmax 35.5.\r\n- ___iopsy revealed diffuse large B cell\r\nlymphoma, CD20+ CD10+ lambda restricted. MIB and cytogenetics \r\nare pending\r\n- ___ C1D1 ICE\r\n\r\nPAST MEDICAL/SURGICAL HISTORY:  \r\nCerebral Aneurysm s/p coil ___ c/b hyperthesia of R V1/V2 \r\n(*Known slight CN VI palsy & mild proptosis of R eye)\r\nHypogammaglobulinemia, \r\nMild GERD\r\nOA / LBP\r\nSmall Intestinal Bacterial Overgrowth\r\nTrochanteric Bursitis\r\ns/p Excisional Bx L Cervical Lymph Node\r\ns/p L total knee replacement ___\r\ns/p I&D Labial Abscess\r\ns/p Excision Cyst R ___ Digit of Hand\r\n\r\n \r\nSocial History:\r\n___\r\nFamily History:\r\nNC\r\n \r\nPhysical Exam:\r\nADMISSION PHYSICAL EXAM:\r\nVS: T 98.3, HR 92, BP 124/78, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\nDISCHARGE PHYSICAL EXAM:\r\nVS: T 98.6, HR 95, BP 114/76, R 20, 97%RA\r\nGeneral: well-appearing but elderly lady, reclined in bed, NAD\r\nHEENT: Normocephalic, R eye ptosis, 1mm vesicle on posterior \r\nsoft palate(chronic per patient), otherwise OP is clear\r\nNeck: 3cm x 1cm L anterior LN, no thyromegaly   \r\nCV: RRR, no r/g/m \r\nLungs: CTA b/l\r\nAbdomen: Soft, NT, ND, +BS\r\nExt: WWP, ___ edema L > R, chronic venous stasis changes noted \r\non b/l shins    \r\nNeuro: Notable for R CN VI palsy & diminished sensation in CN \r\nV-1, also sluggish R CN III response to direct & indirect \r\nillumination, otherwise CN's grossly intact, intact muscle \r\nstrength all extremities, intact light sensation b/l ___\r\nSkin: R pheresis line c/d/i\r\n\r\n \r\nPertinent Results:\r\nADMISSION LABS:\r\n---------------\r\n___ 10:00AM   WBC-5.7 RBC-3.14* HGB-9.8* HCT-28.4* MCV-90 \r\nMCH-31.3 MCHC-34.7 RDW-14.4\r\n___ 10:00AM   NEUTS-72.1* LYMPHS-17.1* MONOS-10.1 EOS-0.2 \r\nBASOS-0.5\r\n___ 10:00AM   PLT COUNT-232#\r\n___ 10:00AM   ___ PTT-29.3 ___\r\n___ 10:00AM   UREA N-11 CREAT-0.7 SODIUM-141 POTASSIUM-4.4 \r\nCHLORIDE-105 TOTAL CO2-25 ANION GAP-15\r\n___ 10:00AM   ALT(SGPT)-17 AST(SGOT)-23 LD(LDH)-311* ALK \r\nPHOS-108* TOT BILI-0.2\r\n___ 10:00AM   ALBUMIN-3.9 CALCIUM-8.6 PHOSPHATE-3.2 \r\nMAGNESIUM-2.1\r\n___ 01:00PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG \r\nGLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-6.0 \r\nLEUK-NEG\r\n___ 01:00PM URINE  COLOR-Straw APPEAR-Clear SP ___\r\n\r\nDISCHARGE LABS:\r\n---------------\r\n___ 05:00AM BLOOD WBC-4.8 RBC-3.06* Hgb-9.6* Hct-28.5* \r\nMCV-93 MCH-31.3 MCHC-33.6 RDW-15.5 Plt ___\r\n___ 05:00AM BLOOD Neuts-78.2* Lymphs-16.9* Monos-4.5 \r\nEos-0.1 Baso-0.4\r\n___ 05:00AM BLOOD ___ 05:00AM BLOOD Glucose-125* UreaN-14 Creat-0.7 Na-142 \r\nK-4.1 Cl-107 HCO3-26 AnGap-13\r\n___ 05:00AM BLOOD ALT-15 AST-14 LD(LDH)-246 AlkPhos-102 \r\nTotBili-0.1\r\n___ 05:00AM BLOOD Calcium-8.6 Phos-3.3 Mg-2.3 UricAcd-3.2\r\n \r\nBrief Hospital Course:\r\nMs. ___ is a ___ year old female with a history of follicular \r\nlymphoma stage IIIA s/p CHOP x 6 in ___ followed by CVP and \r\nthen rituximab x 6 in ___, now with transformed DLBCL who \r\npresents with for cycle 2 of ICE therapy\r\n\r\n# DLBCL: Here for c2 of R-ICE.  c1 R-ICE started ___ and \r\ncompleted without complications. She will need Neupogen D5-12 to \r\nsupport ___.  Will continue bactrim, acyclovir and allopurinol \r\nfor ppx.  Plan for PET-CT after ___ cycle to assess disease \r\nresponse to therapy.  \r\n\r\nCHRONIC ISSUES:\r\n===============\r\n#H/o LLE edema and cellulitis: the pt reports chronic b/l lower \r\nextremity edema s/p L TKR in ___ U/S was negative for DVT \r\non her most recent admission. She also has chronioc venous \r\nstasis and a h/o of MRSA infections (boils, abdominal and \r\nlabial) and on her most recent admission was treated empirically \r\nwith amoxicillin and bactrim. Currently without signs of \r\ninfections and ___ edema at her baseline.\r\n\r\n# Migraines: Takes coffee + indomethacin at home. She received 1 \r\ndose of fioricet for headache during her hospitalization with \r\nrelief of her symptoms.  \r\n\r\n# h/o SVC syndrome s/p thrombectomy. Currently no clinical \r\nevidence SVC thrombus.  She received heparin SC as her platelets \r\nremained >50 during her hospitalization.\r\n\r\n# HLD: continued home statin.\r\n\r\n# Mood: continued home venlafaxine. \r\n\r\n \r\nMedications on Admission:\r\nThe Preadmission Medication list is accurate and complete.\r\n1. Ondansetron 8 mg PO Q8H:PRN nausea \r\n2. Gabapentin 900 mg PO BID \r\n3. Allopurinol ___ mg PO DAILY \r\n4. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n5. Pravastatin 10 mg PO DAILY \r\n6. Furosemide 20 mg PO DAILY \r\n7. Acyclovir 400 mg PO Q8H \r\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n9. Omeprazole 20 mg PO DAILY \r\n10. Venlafaxine 25 mg PO BID \r\n11. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n12. Aspirin 81 mg PO DAILY \r\n13. Multivitamins 1 TAB PO DAILY \r\n\r\n \r\nDischarge Medications:\r\n1. Acyclovir 400 mg PO Q8H \r\n2. Allopurinol ___ mg PO DAILY \r\n3. Aspirin 81 mg PO DAILY \r\n4. Furosemide 20 mg PO DAILY \r\n5. Gabapentin 900 mg PO BID \r\n6. Multivitamins 1 TAB PO DAILY \r\n7. Omeprazole 20 mg PO DAILY \r\n8. Ondansetron 8 mg PO Q8H:PRN nausea \r\n9. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \r\n10. Pravastatin 10 mg PO DAILY \r\n11. Prochlorperazine 10 mg PO Q6H:PRN nausea \r\n12. Sulfameth/Trimethoprim SS 1 TAB PO DAILY \r\n13. Venlafaxine 25 mg PO BID \r\n\r\n \r\nDischarge Disposition:\r\nHome\r\n \r\nDischarge Diagnosis:\r\nDiffuse Large B cell lymphoma\r\n\r\n \r\nDischarge Condition:\r\nMental Status: Clear and coherent.\r\nLevel of Consciousness: Alert and interactive.\r\nActivity Status: Ambulatory - Independent.\r\n\r\n \r\n                             ___ MD ___\r\n \r\nCompleted by: ___\r\n"
        }
      }
    }
  ],
  "collection": "patient"
}
